Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
HOME > REGULATORY
REGULATORY
- Govt Panel Calls for Fact-Finding Study for Annual NHI Price Revision
October 3, 2014
- MHLW Issues Guidelines on Package Insert Updates Mandated under Revised PAL
October 2, 2014
- MHLW Issues Warning on ARB, ACE Inhibitors in Pregnant Women
October 1, 2014
- PMDA Evaluating Xtandi for Risk of Thrombocytopenia
September 30, 2014
- MHLW OKs 19 Products Including MSD’s Insomnia Drug Suvorexant
September 29, 2014
- Daclatasvir/Asunaprevir Combination Therapy for Hepatitis C Now Eligible for Medical Subsidy: MHLW
September 26, 2014
- Govt Panel Approves Plan for Special Zone in Kansai Area Where Mixed-Healthcare Using Unapproved Drugs Will Be Permitted
September 26, 2014
- Editor’s Pick: Five Healthcare News Headlines for September 8 – September 19
September 25, 2014
- Copayment Hike for New Drugs Up for Discussion towards Healthcare Overhaul
September 25, 2014
- MHLW Approves Additional Indications for Aricept, 2 Other Drugs
September 22, 2014
- MHLW Guidelines to Call for Thorough Internal Communications at Pharmas after Novartis’ Delayed ADR Reporting
September 19, 2014
- MHLW Official Concerned about Generic Codevelopment, but Denies Plans to Press for Industry Consolidation
September 19, 2014
- Selexipag, 4 Other APIs Designated as Orphan Drugs
September 19, 2014
- MHLW Launches Discussions on Requirements for Legally Backed Clinical Research Core Hospitals
September 17, 2014
- Regulatory Reform Council to Monitor Progress on Proposed Pricing Overhaul of Innovative Drugs
September 17, 2014
- MHLW Orders Revision of Package Insert for Lyrica
September 17, 2014
- PMDA Issues Alert on Administration of ARBs and ACE Inhibitors in Pregnant Women
September 12, 2014
- US FDA Approves Obesity Treatment Contrave; Takeda Has Marketing Rights
September 12, 2014
- EAD Director to Visit 5 Public Hospital Groups to Encourage Quick Settlement of Price Negotiations
September 12, 2014
- Chuikyo at Odds over Disclosure of Cost-Effectiveness Case Study Data to Companies
September 11, 2014
ページ
Global drug makers are forging ahead with therapies targeting lipoprotein(a), or Lp(a), a promising new approach to reducing cardiovascular risks.…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…